GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to ...

Judi Health launched Judi Rx Retire, an employer-sponsored Medicare Part D plan designed to improve pricing transparency and streamline benefits administration.

As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a foundational ...

The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular ...

A new report on third quarter M&A activity in the healthcare sector found that this quarter’s hospital and health system ...

City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The ...

Rick Abramson, a radiologist by training and the director of FDA's Digital Health Center of Excellence said, "We ended up ...

OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved ...

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera ...

AdvaMed CEO Scott Whitaker outlined four policy priorities at the MedTech Conference: tariffs, FDA user fees, payment and coverage, and cybersecurity.

Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to pay for them, the development pipeline ...

Iambic Therapeutics, an AI-enabled biotech company, will apply the IPO proceeds toward clinical development of its pipeline ...